Kymera Therapeutics Inc. (KYMR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XKLS Summary
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics Q2 Earnings Call Highlights
Kymera Therapeutics NASDAQ: KYMR said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027.
Kymera Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 109 | $5,282.65 | $11,378.51 | $6,095.86 | 115.39% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 1,853 | $212,480 | $199,234.56 | -$13,245.44 | -6.23% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 36,368 | $1.67M | $3.91M | $2.24M | 134.34% |
| BG Bart Gancher Intech Investment Management LLC | 12,412 | $682,859.76 | $1.33M | $651,678.48 | 95.43% |
 John H. Burbank III Passport Capital LLC | 8.66M | $354.03M | $1.02B | $662.24M | 187.06% |
Kymera Therapeutics Inc. (KYMR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kymera Therapeutics Inc. ever had a stock split?
Kymera Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Nello Mainolfi CEO | NASDAQ (NMS) Exchange | 501575104 CUSIP |
| US Country | 273 Employees | - Last Dividend | - Last Split | 21 Aug 2020 IPO Date |
Overview
Kymera Therapeutics, Inc. is a pioneering biopharmaceutical company committed to the discovery and development of innovative small molecule therapeutics that leverage the body’s natural protein degradation system to specifically target and eliminate disease-causing proteins. Established in 2015 and based in Watertown, Massachusetts, Kymera Therapeutics is at the forefront of harnessing proteolysis targeting chimeras (PROTACs) technology to address some of the most challenging diseases in immunology, oncology, and other fields.
Products and Services
- IRAK4 Program
This program is a testament to the company’s innovative approach, currently in Phase II clinical trial targeting a range of immunology-inflammation diseases such as hidradenitis suppurativa and atopic dermatitis. By focusing on the selective degradation of the IRAK4 protein, Kymera aims to offer novel treatments for conditions with significant unmet needs.
- STAT3 Program
Geared towards the treatment of hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis, the STAT3 program represents Kymera Therapeutics' venture into oncology and autoimmune disorders. Leveraging the degradation of STAT3, this program seeks to provide effective therapies for diseases that are currently hard to treat.
- MDM2 Program
Another highlight in Kymera’s pipeline is the MDM2 program, dedicated to addressing both hematological malignancies and solid tumors. By exploiting the degradation pathway of the MDM2 protein, this program explores new horizons in cancer treatment, showcasing the flexibility and potential of PROTACs technology.
- STAT6
The STAT6 project focuses on tackling Type 2 inflammation present in allergic diseases. Through the selective degradation of the STAT6 protein, Kymera Therapeutics is venturing into the realm of allergy and immunology, aiming to develop therapies that can significantly improve patient outcomes in allergic conditions.
- TYK2
Addressing inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus, the TYK2 program underscores Kymera Therapeutics' commitment to inflammatory diseases. By targeting the TYK2 protein for degradation, the company is working on crafting innovative solutions that could transform the treatment landscape for patients suffering from these chronic conditions.
